(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead Sciences, Inc. (GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to combat AIDS, ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced that it has signed an access agreement with Pharmaceutical Company Gilead Sciences to procure lenacapavir, a ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

The Minister of Health, Dr. Sabin Nsanzimana, has cautioned that despite progress made in combating HIV/AIDS, the virus remains a serious threat and is increasingly re-emerging among young people. The ...

The National Agency for the Control of AIDS (NACA) is set to host a high-level meeting to deliberate on sustainable ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Nigeria must take bold steps to ensure that HIV prevention, treatment, and support remain accessible and resilient, ...